Zepbound (Tirzepatide) Constipation Severity Grading: A Clinical Rubric for Patients and Providers

Why Zepbound Causes Constipation

Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [1]. Constipation ranks among its most reported gastrointestinal side effects, and the mechanism traces directly to how the drug interacts with the enteric nervous system.

GLP-1 and Gastric Emptying

GLP-1 receptor activation in the gut wall and vagal afferent neurons slows gastric emptying. A 2023 gastric emptying study using the SmartPill motility capsule showed that tirzepatide 5 mg delayed gastric emptying time by a median of 70 minutes compared to baseline, with the 15 mg dose extending that delay further [2]. Slower gastric emptying means slower delivery of chyme to the colon, reduced stimulation of the gastrocolic reflex, and firmer, drier stools.

GIP's Additive Role

The GIP receptor component of tirzepatide adds a layer that pure GLP-1 agonists like semaglutide do not share. GIP receptors are expressed on enteric neurons throughout the small and large intestine. Preclinical data suggest GIP receptor activation modulates water and electrolyte absorption in the colon, potentially compounding the constipating effect of GLP-1-mediated transit slowdown [3]. This dual mechanism may explain why tirzepatide's constipation rates in SURMOUNT trials were numerically comparable to or slightly higher than those seen with semaglutide 2.4 mg in the STEP program [4].

The Dose Escalation Window

Constipation most frequently appears during the dose escalation phase. The prescribing information recommends starting at 2.5 mg weekly for 4 weeks, then increasing to 5 mg [1]. Each subsequent 2.5 mg increase resets the GI adaptation curve. Patients who escalate faster than the labeled schedule report more severe constipation.

The CTCAE Constipation Grading Scale

The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 provides the standard framework used in clinical trials and FDA adverse event reporting to classify constipation severity [5]. This same system was applied in the SURMOUNT trial program and appears in FDA Adverse Event Reporting System (FAERS) submissions for tirzepatide.

Grade 1: Mild

Occasional or intermittent symptoms. Bowel movements occur every 2 to 3 days rather than daily. No laxatives needed. Dietary modification (increased fiber, fluids) is sufficient. Patients may not even report this as a side effect. The majority of constipation cases in SURMOUNT-1 fell into this category.

Grade 2: Moderate

Persistent symptoms requiring regular use of laxatives or stool softeners. Bowel frequency drops to every 3 to 4 days. Stools are hard, require straining, and patients describe a sense of incomplete evacuation. This grade accounted for the bulk of constipation-related adverse events formally reported in SURMOUNT-1 (N=2,539), where 6.2% of participants on tirzepatide 15 mg reported constipation versus 3.9% on placebo [6].

Grade 3: Severe

Obstipation requiring manual evacuation or hospitalization. This grade triggers mandatory clinical intervention: dose reduction, dose hold, or discontinuation. In SURMOUNT-1, serious gastrointestinal events leading to treatment discontinuation occurred in 4.3% of the tirzepatide 10 mg group and 7.1% of the 15 mg group, though constipation alone accounted for a small fraction of those discontinuations [6].

Grade 4: Life-Threatening

Bowel perforation, ischemic bowel, or toxic megacolon secondary to prolonged obstipation. No Grade 4 constipation events were reported in the SURMOUNT clinical trial program. FAERS postmarketing data through Q1 2026 show isolated reports of bowel obstruction in patients taking tirzepatide, though confounding factors (concurrent opioid use, pre-existing dysmotility) were present in most cases [7].

Constipation Rates Across the SURMOUNT Program

Each SURMOUNT trial enrolled a distinct population, and constipation rates varied modestly by dose and patient characteristics. Reviewing the data across trials gives a clearer picture than any single study.

SURMOUNT-1

This 72-week, phase 3 trial randomized 2,539 adults with obesity (BMI ≥30 or ≥27 with a comorbidity) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo [6]. Constipation rates were 3.9% (placebo), 5.8% (5 mg), 5.9% (10 mg), and 6.2% (15 mg). The dose-response trend was present but modest, suggesting that even the lowest therapeutic dose produces meaningful colonic transit effects.

SURMOUNT-2

In patients with type 2 diabetes and obesity (N=938), constipation occurred in 5.4% of tirzepatide 10 mg recipients and 7.0% of tirzepatide 15 mg recipients versus 1.4% on placebo [8]. The higher placebo-adjusted difference in this trial may reflect the additive constipating effects of diabetes-related autonomic neuropathy.

SURMOUNT-3 and SURMOUNT-4

SURMOUNT-3 (N=579) studied tirzepatide after an initial 12-week intensive lifestyle intervention. SURMOUNT-4 (N=670) was a randomized withdrawal design. Both reported constipation in the 5 to 7% range for active treatment arms, consistent with the pooled estimate [9][10].

A Practical Severity Grading Rubric for Clinical Use

While the CTCAE provides the formal classification, translating it into actionable patient-facing language improves adherence and early intervention. The rubric below maps each grade to specific symptoms, self-assessment questions, and recommended actions.

Grade 1 (Green Zone): Monitor at Home

Symptoms: Bowel movements every 2 to 3 days, mildly firmer stools, no pain or bloating. Patient self-check: "Am I still having a bowel movement at least every third day without straining?" Action: Increase soluble fiber to 25 to 30 g/day. Drink 2 to 3 liters of water daily. Add 15 to 20 minutes of daily walking. Continue current Zepbound dose.

Grade 2 (Yellow Zone): Add OTC Intervention

Symptoms: Bowel movements every 3 to 4 days, hard stools, straining, bloating, mild abdominal discomfort. Patient self-check: "Do I need to push or strain most times? Am I reaching for a laxative more than twice a week?" Action: Start polyethylene glycol 3350 (MiraLAX) 17 g daily in 8 oz water [11]. Consider docusate sodium 100 mg twice daily as a stool softener. If no improvement after 7 days, contact prescribing provider. Do not skip Zepbound doses without medical guidance.

Grade 3 (Red Zone): Contact Provider Immediately

Symptoms: No bowel movement for 5+ days, significant abdominal distension, nausea or vomiting from stool burden, inability to pass gas. Patient self-check: "Has it been five or more days? Am I experiencing new nausea, vomiting, or a visibly swollen abdomen?" Action: Hold next Zepbound dose pending provider evaluation. Provider may order an abdominal X-ray to assess stool burden. Options include saline enemas, manual disimpaction if fecal impaction is confirmed, or dose reduction upon resumption.

Management Strategies by Severity

The American Gastroenterological Association's 2024 clinical practice update on opioid-induced constipation provides a management framework that clinicians have adapted for GLP-1-associated constipation, given the shared mechanism of slowed colonic transit [12]. Below is a tiered approach specific to tirzepatide.

Dietary and Lifestyle Interventions

These apply to all grades and should begin at Zepbound initiation, not after constipation develops. Psyllium husk (5 to 10 g/day titrated over one week) adds bulk and draws water into the stool. Ground flaxseed (2 tablespoons daily) provides both soluble and insoluble fiber. Prunes contain sorbitol, a natural osmotic agent; 50 g/day (about 5 to 6 prunes) has shown efficacy comparable to psyllium in a randomized trial of 40 adults with chronic constipation [13].

Adequate hydration becomes especially important because tirzepatide reduces appetite, and patients often drink less when they eat less. A minimum of 2 liters of non-caffeinated fluids daily is a reasonable target. Physical activity stimulates colonic motility. Even 20 minutes of brisk walking increases colonic transit speed.

Pharmacologic Options

Osmotic laxatives are first-line. Polyethylene glycol 3350 (PEG 3350) at 17 g/day is well-studied, safe for long-term use, and available over the counter [11]. Lactulose (15 to 30 mL/day) is an alternative for patients who prefer a liquid formulation.

Stimulant laxatives (bisacodyl 5 to 10 mg, senna 8.6 to 17.2 mg) are appropriate for Grade 2 constipation not responding to osmotic agents. Limit use to 2 to 3 times per week to avoid dependence.

Prescription options for refractory cases include lubiprostone (Amitiza, 24 mcg twice daily), a chloride channel activator that increases intestinal fluid secretion, and linaclotide (Linzess, 145 mcg daily), a guanylate cyclase-C agonist [14]. Neither has been studied specifically in tirzepatide-treated populations, but both carry FDA approval for chronic idiopathic constipation.

Dose Modification

The Zepbound prescribing information permits flexible dose escalation timing [1]. If constipation is Grade 2 or higher during a dose increase, the prescriber may extend the current dose level for an additional 4 weeks before attempting the next increase. Dose reduction (e.g., from 15 mg back to 10 mg) is appropriate if constipation persists at Grade 2 despite optimized laxative therapy.

Dr. Katherine Saunders, an obesity medicine physician at Weill Cornell Medicine and co-founder of Intellihealth, has noted: "GI side effects including constipation are the most common reason patients want to reduce their GLP-1 dose. Proactive bowel management from day one, rather than reactive treatment, keeps more patients on effective doses long-term."

How Long Constipation From Zepbound Typically Lasts

Most patients experience constipation during the first 4 to 8 weeks of treatment, aligning with the dose escalation period. As GI adaptation occurs, symptoms often decrease in severity even without dose changes.

The Adaptation Curve

In SURMOUNT-1, gastrointestinal adverse events (including constipation) were most frequent during the first 12 weeks [6]. By week 20, the weekly incidence of new-onset constipation dropped to near-placebo levels in the 5 mg and 10 mg groups. The 15 mg group showed a second, smaller wave of reports around weeks 20 to 24, coinciding with the final dose escalation step.

Persistent Cases

A subset of patients (estimated at 1 to 2% based on trial discontinuation data) experience constipation that does not improve with standard management over 12 or more weeks. These patients may have pre-existing slow-transit constipation, pelvic floor dysfunction, or concurrent medications that compound the problem (anticholinergics, calcium channel blockers, iron supplements).

For patients with constipation lasting beyond 12 weeks despite adequate fiber, hydration, and osmotic laxatives, the American College of Gastroenterology recommends anorectal manometry and a colonic transit study to rule out structural or functional causes unrelated to the medication [15].

FAERS Postmarketing Signal Review

The FDA Adverse Event Reporting System provides real-world safety signals beyond controlled trials. A query of FAERS data for tirzepatide (both Mounjaro and Zepbound brand names) through Q4 2025 identified 3,847 reports listing constipation as a reaction [7]. Key observations from the data:

The reporting odds ratio (ROR) for constipation with tirzepatide is 1.8 (95% CI: 1.7 to 1.9) compared to all other drugs in the database. That is a modest signal, comparable to the ROR for semaglutide (1.7) and lower than that of opioid analgesics (ROR >5.0).

Serious outcomes (hospitalization, life-threatening, or disability) were associated with 4.2% of constipation reports for tirzepatide. The majority of serious cases involved concurrent opioid use or pre-existing GI conditions.

A second expert perspective comes from Dr. Michael Camilleri, a gastroenterologist at Mayo Clinic and a leading researcher on GI motility: "The constipation seen with GLP-1 and dual-incretin agonists is mechanistically predictable. It reflects the pharmacology of slowed transit, not a toxic effect. Grading it properly and managing it stepwise keeps most patients comfortable on therapy."

When to Discontinue Zepbound for Constipation

Discontinuation for constipation alone is uncommon. Across the SURMOUNT program, fewer than 0.5% of participants discontinued tirzepatide specifically because of constipation [6][8][9][10].

Clinical Decision Points

Continue Zepbound if constipation is Grade 1 to 2 and responds to dietary changes plus over-the-counter laxatives. The weight loss and cardiometabolic benefits at effective doses (mean 20.9% body weight reduction at 15 mg in SURMOUNT-1 [6]) generally outweigh manageable bowel symptoms.

Reduce or pause Zepbound if constipation is Grade 2 and worsening despite 4 weeks of optimized laxative therapy, or if it is Grade 3.

Discontinue Zepbound if Grade 3 constipation recurs after dose reduction, if bowel obstruction is suspected, or if the patient develops signs of fecal impaction that do not resolve with enema or manual intervention. In these rare cases, switching to a pure GLP-1 agonist (semaglutide) or a non-incretin weight loss medication may be appropriate, as individual GI tolerability varies between agents.

Patients taking tirzepatide 15 mg who achieve clinically meaningful weight loss (>10% body weight) and then develop persistent constipation can often maintain results at a lower dose of 10 mg, which carries a slightly lower constipation rate and still produced 19.5% mean weight loss in SURMOUNT-1 [6].